Gestational-Trophoblastic-Disease-Autosaved

Gestational Trophoblastic Disease

Overview

  • Gestational trophoblastic disease (GTD), also known as molar pregnancy, involves abnormal placenta development.

  • Characterized by the conversion of chorionic villi into a mass of clear vesicles.

  • Fetus may be absent, or there may be a degenerating fetus.

  • Includes conditions such as:

    • Complete hydatidiform moles

    • Partial hydatidiform moles

    • Invasive moles

    • Gestational choriocarcinomas

    • Placental site trophoblastic tumors

  • Occurrence rate: 1 in 1,500 pregnancies or 1 in 600 therapeutic abortions.

  • Typically diagnosed in the first trimester and may require chemotherapy.

Types of Gestational Trophoblastic Disease

Benign

  • Hydatidiform Mole (Molar Pregnancy)

Malignant

  • Gestational Trophoblastic Neoplasia

    • Includes choriocarcinoma and other trophoblastic tumors.

Embryonic Development

Process

  • At fertilization, a female gamete (egg) fuses with a male gamete (sperm).

  • Each gamete contains 23 chromosomes, forming a zygote with 46 chromosomes.

  • Zygote undergoes repeated mitosis, forming inner and outer layers:

    • Inner cells develop into the embryo.

    • Outer cells (trophoblasts) form the chorion and chorionic villi.

  • Chorion produces beta-hCG, crucial for pregnancy maintenance.

Trophoblastic Cells

  • Responsible for nutrient attachment and sustenance from the placenta.

  • Produce HCG, which detects and maintains pregnancy.

  • Loss of regulatory control leads to abnormal tissue proliferation, invading the myometrium.

Risk Factors

  • Age extremes (under 16 or over 45).

  • Personal history of GTD.

  • Increased incidence in individuals of Asian descent.

Clinical Manifestations

  • Signs and Symptoms:

    1. First-trimester vaginal bleeding.

    2. Absence of fetal heart tones and structures.

    3. Uterine enlargement greater than expected (doubling size if complete mole).

    4. Elevated β-hCG titers per gestational age.

    5. Expulsion of vesicles.

    6. Hyperemesis gravidarum (severe nausea/vomiting).

    7. Early-onset preeclampsia (first half of pregnancy).

Management

  • Approximately 20% of patients may develop malignancy, requiring chemotherapy post-evacuation of hydatidiform moles:

    1. Suction curettage for evacuation; laparotomy rare.

    2. Serial β-hCG tests to track resolution to baseline (<5 mIU/mL).

    3. Hormonal contraception during monitoring.

    4. Chemotherapy for malignant cases.

    5. Administer RhIG if the woman is Rh negative.

Diagnostic Evaluation

  • Excessive β-hCG levels indicate potential GTD.

  • Ultrasound reveals diffuse echogenic patterns and absence of fetal development.

Complications

  1. Significant blood loss.

  2. Potential for malignancy.

  3. Risk of infertility.

Nursing Assessment

  • Key Assessments:

    1. Monitor vital signs and symptoms of preeclampsia.

    2. Assess vaginal bleeding and any additional discharge.

    3. Evaluate for proteinuria.

    4. Record the date of last menstrual period (LMP) and positive pregnancy test.

    5. Measure fundal height and compare to LMP.

    6. Review CBC results and Rh type.

Nursing Diagnoses

  • Risk for Deficient Fluid Volume related to hemorrhage.

  • Anxiety associated with pregnancy loss and medical interventions.

Maintaining Fluid Volume

  1. Blood type and crossmatch samples; prepare for possible transfusion.

  2. Establish peripheral IV access using a large needle (16-18G).

  3. Regularly assess vital signs and evaluate bleeding severity.

  4. Monitor lab results to assess patient status.

Decreasing Anxiety

  1. Inform the patient about preoperative and postoperative care.

  2. Educate on the disease process; cover both acute and chronic aspects.

  3. Allow family to grieve potential loss of pregnancy and future fertility.

Patient Education and Health Maintenance

  1. Stress the importance of continuous follow-up care.

  2. Reinforce follow-up procedures extending up to a year post-diagnosis.

  3. Encourage discussions about care and fertility options with healthcare providers.

Expected Outcomes

  • Stable vital signs and normal lab results.

  • Patient verbalizes concerns and understanding of follow-up care.